The Metis platform combines AI data-driven algorithms, mechanism-driven quantum mechanics, and molecular dynamic simulations to calculate active pharmaceutical ingredient (API) properties and elucidate API target and API excipient interactions. In addition, the platform can predict chemical, physical, and pharmacokinetic properties of small molecule and nucleic acid therapeutics in specific microenvironments, which can enable efficient lead optimization, candidate selection, and formulation design, Metis said.

PICC PE and China Life led the financing; they were joined by Sequoia Capital China, Lightspeed, 5Y Capital, Frees Fund, and CMBI Zhaoxin Wuji Fund.

New machine-learning approach promises to speed drug design
A new approach to machine learning outperformed current machine-learning methods in drug design, demonstrating its potential in speeding up the drug discovery...

Red Cell forms Zephyr AI
Red Cell has formed Zephyr AI to transform drug discovery and precision medicine through the integration of artificial intelligence (AI).